4th RNA-Seq San Francisco April 26-28 Event Guide

April 26 - 28, 2016
San Francisco, CA
24 Expert Speakers Including:
Lead Partner: Additional Partners:
www.rna-seqsummit.com
Researched & Developed By:
Tel: +1 212 537 5898 | Email: info@hansonwade.com RNA-Seq Forum
• Harnessing the Full Potential of
Single-Cell RNA-Seq
• Reinventing Analytical Strategies to Deal with
the Vast Complexity of the Transcriptome
• Advancing the Clinical Applications of
RNA-Seq Technology
2016
RNA-Seq 2016 San Francisco | April 26-28, 2016
Paul Rejto
Head of Precision
Medicine, Oncology
Research Unit
Pfizer
Yasuhiro Funahashi
Senior Director,
Biomarkers and
Personalized Medicine
Core Function Unit
Eisai
®
Chris Mason
Principal Investigator and
Associate Professor
Weill Cornell Medical
College
Ganesh Sathe
Head of DNA Sequencing
GSK
Dongliang Ge
Director, Computational
Biology
Gilead Sciences
Garry Nolan
Professor, Microbiology
& Immunology
Stanford University
@RNASeq_Summit

RNA-Seq Forum
1 6
3 8
2 7
4 9
5 10
Welcome to RNA-Seq 2016
Tel: +1 212 537 5898 Email: info@hansonwade.com
@RNASeq_Summit
Realize the Practical Applications of RNA-Seq
In an industry that is constantly evolving, the integration
and application of RNA-Seq technologies to improve
drug discovery and development is gaining significant
momentum.
RNA-Seq 2016 will help expert scientists,
bioinformaticians and business leaders devise
collaborative solutions to streamline technology and
maximize the practical applications of RNA-Seq.
Critically, this year’s agenda has been designed
specifically for the RNA-Seq community by fore-thinkers
in the industry with a greater focus on single-cell
RNA-Seq, bioinformatics approaches and the clinical
applications of RNA-Seq. By engaging with our expert
speaker line-up, you will get the chance to hear the most
up to date case studies, intellectual insight and be part
of this thought provoking discussion.
Join the 4th annual RNA-Seq meeting to evaluate the
latest advances in RNA-Seq, and discover how to fully
utilize this technology to advance disease understanding
and therapeutic intervention.
Harness the full potential of single-cell
RNA-Seq to revolutionize the way we
approach disease research
Implement specific bioinformatic systems for
accurate analysis of clinical genomic studies
Top 10 Reasons to Attend RNA-Seq 2016
Develop analytical strategies to accurately
interpret the vast complexity of the
transcriptome and efficiently source
the most valuable information
Successfully utilize metatranscriptomics to
advance progression in microbiome disease
research
Identify innovative, cutting edge methodologies
to improve single-cell sequencing throughput
and efficiency
Engage in debate with bioinformaticians and
biologists to streamline the RNA-Seq process
from the bench to the computer
Understand how to effectively develop
RNA-Seq technologies into
clinically applicable tools
Identify methods of commercializing
RNA-Seq for biomarker detection and
as a clinical diagnostic tool
Successfully integrate RNA-Seq with the
other omic studies to generate combinatorial
strategies for furthering disease understanding
Overcome the shortfalls in current RNA-Seq
technologies to drive the evolution of cheaper
and more efficient systems
Some of the brightest minds and industry leaders in genomics for a
series of illuminating seminars and beneficial meetings.
Bina Technologies
RNA-Seq Attendee

RNA-Seq Forum
Speakers
www.rna-seqsummit.com @RNASeq_Summit
Yasuhiro Funahashi
Senior Director,
Biomarkers &
Personalized Medicine
Core Function Unit
Eisai
Jeff Brockman
Principal Scientist
Hill’s Pet Nutrition
Tim Mercer
Lab Head, Transcriptomic
Research
Garvan Institute of Medical
Research
Alex Shalek,
Assistant Professor
of Health Sciences &
Technology
MIT
Alex Mackenzie
Principal Investigator,
Apoptosis Research
Centre
CHEO Research
Institute
Zoltan Dezso
Principal Scientist, Human
Biology & Data Sciences
Engine
Eisai
Magnolia Bostick
Scientist III
Takara Clontech
Jamie Hill
Senior Bioinformatics
Scientist
QIAGEN
Saumya Pant
Head of Sequencing
Technologies
Bristol-Myers Squibb
Xiang (Sean) Yao
Principal Scientist
CS - Computational &
System Biology
Janssen
Alex Pollen
Damon Runyon
Postdoctoral Fellow
UCSF
Karsten Zengler
Associate Professor,
Division of Host-Microbe
Systems & Therapeutics
University of California,
San Diego
Kejie Li
Computational Biologist
Biogen Idec
Jadwiga Bienkowska
Biology
Pfizer
Josh Kaminker
Senior Scientist,
Bioinformatics &
Computational Biology
Genentech
Garry Nolan
Professor, Microbiology &
Immunology
Stanford University
Jin Jen
Co-Director, Genome
Analysis Core, Medical
Genome Facility
Mayo Clinic
Dongliang Ge
Biology
Gilead Sciences
Kelli Bramlett
Leader RNA Sequencing
Applications Team, Life
Sciences Solutions
Thermo Fisher Scientific
Stefan McDonough
Senior Director &
Head of Neurogenetics
Pfizer
Paul Rejto
Head of Precision
Medicine, Oncology
Research Unit
Pfizer
Ganesh Sathe
Head of DNA Sequencing
GSK
Jean-Noel Billaud
Principal Scientist
QIAGEN
Chris Mason
Principal Investigator &
Assistant Professor
Weill Cornell Medical College

RNA-Seq Forum
@RNASeq_Summit
8.20 Chair’s Opening Remarks
8.30 Keynote Presentation: Towards a Cellular & Molecular Resolution
Map of Cerebral Cortex Development
• Creating a cellular resolution map of gene expression in the developing human
neocortex to unravel the diversity of neuronal lineages and to support strategies for
targeting and replacing specific cell types in the brain
• Analyzing gene expression across single cells to identify the outer subventricular
zone radial glia preferentially express genes that may help to establish a self-
sustaining proliferative stem cell niche
• Developing strategies to integrate data from single cell genomics with studies of
morphology, position, cell behavior, developmental fate potential, and physiology
Alex Pollen, Damon Runyon
Postdoctoral Fellow, UCSF
The Single-Cell RNA-Sequencing Revolution
9.00 Addressing Cancer Heterogeneity at the Single-Cell Level
• Effectively utilizing single-cell RNA-Seq to elucidate tumor heterogeneity
• Identifying epigenetic drivers of gene expression heterogeneity in cancer using single-
cell RNA-Seq
• Efficiently analyzing and integrating transcriptional and epigenetic data in cancer
genomics research
Chris Mason, Principal
Investigator and Associate
Professor, Weill Cornell Medical
College
9.30 Successfully Deconvolving Heterogeneous Systems Using
Single-Cell RNA-Seq to Increase Disease Understanding
• Improving understanding of cellular heterogeneity in the context of disease progression
• Identification of cell differentiation with relevance to homeostasis and disease
pathogenesis
• Analyzing the discovery of detailed cellular phenotypes to drive target identification and
therapeutic discovery
Alex Shalek, Assistant Professor
of Health Sciences & Technology,
MIT
10.00 Morning Refreshments & Speed Networking
11.00 Utilizing Single-Cell RNA-Seq For Fluid Biopsies Analysis
• Deploying single-cell RNA-Seq for clinically accurate analysis of disease biopsies
• Overcoming the hurdles of analyzing biofluid RNA samples with single-cell sequencing
• Adapting experimental design and analytical methods to accommodate for biofluid RNA
sample input
• Identification of current obstacles to single-cell RNA-Seq to streamline single-cell
RNA-Seq pipelines
Saumya Pant, Head of
Sequencing Technology,
Bristol-Myers Squibb
11.30 The Billion Cell Barcode Revolution
• Harnessing split pool synthesis combinatorial chemistry as an alternative approach
in single-cell sequencing to barcode billions of cells without cellular isolation
• Understanding how to successfully integrate split pool synthesis into an single-cell
RNA-Seq pipeline
• Applying this revolutionary protocol in a disease specific context
Garry Nolan, Professor,
Microbiology & Immunology,
Stanford
12.00 Networking Lunch
Tackling Functional Transcriptome Complexity
1.00 Systematic Integration of RNA-Seq Data & Application to Drug
Discovery Research
• Integration internal and external RNA-Seq data, such as GTEx and ENCODE, through
consistent data processing and cross-linking
• Multi-tier management of different RNA-Seq data types and access levels
• Application of integrative RNA-Seq analysis to drug discovery, especially in various
aspects of target identification and validation
Xiang (Sean) Yao, Principal
Scientist, CS - Computational
and System Biology, Janssen
1.30 Overview of RNA-Seq Applications in Cancer Drug Discovery
• Utilizing RNA-Seq in cancer drug discovery will be reviewed with applications to
target discovery, undercovering mechanisms of resistance, and providing insight into
predictive markers for response to therapy
• Analyzing future directions and new applications including liquid biopsies, rare cell
populations and poor quality tissue
Paul Rejto, Head of Precision
Medicine, Oncology Research
Unit, Pfizer
Conference Day One, April 27, 2016

RNA-Seq Forum
@RNASeq_Summit
2.00 Defining RNA Quality Control Metrics to Improve the Study of Full
Transcriptional Complexity
• The design, manufacture and validation of synthetic genes for bioinformatics analysis
of gene expression, transcript assembly and fusion gene diagnostics
• Comprehensive analysis of human chromosome 21: detailing the full extent of
transcriptome size and complexity
• Identification of fundamental distinctions between coding and non-coding gene
organisation, splicing and evolution
Tim Mercer, Lab Head,
Transcriptomic Research,
Garvan Institute of Medical
Research
2.30 RNA-Seq Simplified! Targeted NGS Approaches to RNA Analysis
• Discussing the use of Ion AmpliSeq™ technology for targeted RNA analysis
• Analysis of data confirming high sensitivity, broad dynamic range and
assay robustness
• Utilizing this approach for gene pathway analysis, gene fusion detection, and
transcriptome analysis
Kelli Bramlett, Leader, RNA
Sequencing Applications Team,
Life Sciences Solutions, Thermo
Fisher Scientific
2.40 Using RNA-Seq to Study the Gastrointestinal Tract of the Dog
• Addressing RNA integrity and endogenous RNAse expression in the upper sections
of the GI tract
• Defining functional compartments of the GI tract through utilization of gene
expression patterns
• Studying the correlation between specific mRNA expression levels and attachment of
gut microflora
Jeff Brockman, Principal
Scientist, Hill’s Pet Nutrition
3.10 Afternoon Refreshments & Networking
3.40 NGS & RNA-Seq in Cancer Immune Therapy
• Utilizing RNA-Seq to Study Protein-RNA interactions
• Understanding how RNA-Seq can be used to study the impact of differential exon
expression on protein function
• Employing RNA-Seq in conjunction with other sequencing methods for the
identification and observation of protein-RNA interactions in subcellular detail
Jadwiga Bienkowska, Director,
Computational Biology, Pfizer
4.10 Deciphering the Cellular Complexities of Neurodegenerative
Disease using RNA-Seq
• Developing novel methods to purify specific populations of cells from whole brain
• Performing RNA-Seq analysis using low quantity and low quality RNA
• Transcriptomic analysis identifies cell specific expression and splicing changes in
neurodegenerative disease
Josh Kaminker, Senior Scientist,
Bioinformatics & Computational
Biology, Genentech
4.40 Panel Discussion: The Significance of Transcriptome Complexity
• Evaluating RNA sequencing technologies and bioinformatic tools that resolve
transcriptome complexity.
• Debating the functional importance of pervasive transcription, long noncoding RNAs,
and isoform diversity generated by extensive alternative splicing.
• Discussing the role of transcriptome complexity in evolution, development
and disease
Tim Mercer, Lab Head,
Transcriptomic Research, Garvan
Institute of Medical Research
Alex Shalek, Assistant Professor
of Health Sciences and
Technology, MIT
Jeff Brockman, Principal
Scientist, Hill’s Pet Nutrition
Josh Kaminker, Senior Scientist,
Bioinformatics & Computational
Biology, Genentech
Alex Pollen, Damon Runyon
Postdoctoral Fellow, UCSF
5.20 Round Table Session
This session will focus on devising solutions that cannot be obtained in presentation format, and will give you actionable
takeaways to build a more holistic understanding of the field. Access the critical information that is only obtainable through
frank and open discussion around crucial topics in the field. Shape the debate around the following topics:
• How many cells do you need? – e.g. What are the drivers of the quantity of single cells you need to look at for your
experiment
• Single Cell RNA Seq Bioinformatics
• The power of full length transcript RNAseq – e.g. when to run full length transcript vs 3’ end counting to answer you
biological question
6.20 Chair’s Closing Remarks
6.30 Networking Drinks Reception hosted by Fluidigm
®
®

RNA-Seq Forum
@RNASeq_Summit
8.50 Chair’s Opening Remarks
Analyzing the Clinical Applications of RNA Sequencing
9.00 Panel Discussion: Debating the Clinical Applications of RNA-Seq
• Understanding the approval standards for clinical applications of RNA-Seq
• Revamping the regulatory system to support the innovation and application of RNA-
Seq in the clinic
• Defining the regulatory framework to identify the procedures for delivering clinically
useful RNA-Seq products
• How to best analyze, interpret and present RNA-Seq data to maximize a clinically
relevant output
• Incorporating RNA-Seq into clinical management and practices: identifying how to
best utilize RNA-Seq in the clinic
Ganesh Sathe, Head DNA
Sequencing, GSK
Stefan McDonough, Executive
Director, Research, Amgen
9.45 Utilizing RNA-Seq for Translational Research to identify Biomarker
for Anticancer Agents Targeting Tumor Microenvironment
• Employing RNA-Seq for cancer biomarker research to target tumor
microenvironment
• Issues of RNA-Seq analysis and targeting approach with other methods to promote
translation science in clinical biomarker
• Discussing the utility of RNA-Seq analysis based on examples of the translational
research for our anticancer drugs
Yasuhiro Funahashi, Senior
Director, Biomarkers and
Personalized Medicine Core
Function Unit, Eisai
10.15 Harnessing the Potential of RNA-Seq as a Clinical Diagnostic Tool
• Employing transcriptome profiling for disease analysis and compound verification
• How to best use differential gene expression signatures to identify small molecules
for compound screening
• Utilizing RNA-Seq technology for accurate profiling and analysis of ALS
neurodegenerative disease
Ganesh Sathe, Head DNA
Sequencing, GSK
10.45 New Applications Leveraging RNA Sequencing using
SMART Technology
• Three new applications for low input RNA analysis
• Using SMART technology to generate libraries for RNA profiling for:
• Small RNAs
• TCR (T cell receptor)
• Single cells using the Fluidigm C1
Magnolia Bostick, Scientist III,
Takara Clontech
10.55 Morning Refreshments & Networking
11.30 Overcoming RNA Quality Issues to Enable High Quality Whole
Transcriptome Sequencing
• Critical factors affecting the quality of RNA in clinical and research settings
• Optimized protocols for RNA-Seq using challenging and partially degraded samples
• Clinical applications of RNA-Seq to enhance cancer diagnosis and
treatment stratification
Jin Jen, Co-Director, Genome
Analysis Core, Mayo Clinic
12.00 Harnessing RNA-Seq in Drug Repurposing for Rare
Genetic Disorders
• Utilizing RNA-Seq to validate specific rare diseases as potential candidates for drug
repurposing programs
• Devising analytical strategies to identify potential drugs that transcriptionally modulate
specific disease genes
• Proving efficacy of potentially repurposable drugs and the restoration of normal genetic
function using RNA-Seq
Alex Mackenzie, Principal
Investigator, CHEO Research
Institute
Conference Day Two, April 28, 2016

RNA-Seq Forum
@RNASeq_Summit
12.30 Networking Lunch
1.30 Overcoming Bioinformatic Challenges in Clinical Genomics
• Identifying the key big data issues in drug discovery and development
• Choosing a big data strategy for biomarker development
• Discussing common pitfalls when planning an NGS led study
• Best practices in the evaluation of the quality of NGS data
Dongliang Ge, Director
Computational Biology, Gilead
Sciences
2.00 Application of Single Cell RNA-Seq on Clinical Biopsy Material
at Biogen
• Benchmarking study of the comparison of RNA-Seq to other profiling platforms
• Findings of single cell RNA-Seq analysis of clinical biopsy sample
• For extreme low amount of biopsy sample, reconstituting single cell RNA-Seq profiles
to bulk sample like profile as an alternative
Kejie Li, Computational Biologist,
Biogen Idec
2.30 Afternoon Refreshments & Networking
3.00 Utilizing RNA-Seq Data for Biomarker Research in Cancer
Immunotherapy
• Identifying the immunophenotypes of different types of cancer by applying
computational methods on large scale RNA-Seq data
• Exploring how cancer immunophenotyping supports patient stratification and
biomarker research in cancer immunotherapy
• Understanding the relationship between cancer immunophenotypes with immune
genes and signaling pathways based on RNA-Seq expression profiling
Zoltan Dezso, Principal Scientist,
Human Biology & Data Sciences
Engine, Eisai
3.30 Panel Discussion: Creating Efficient Collaborations Between
Bioinformaticians & Biologists to Harmonize RNA-Seq Procedures
• Streamlining the RNA-Seq process between the bench and computer
• Matching experimental design and analytical strategies to accurately and efficiently
interpret RNA-Seq data
• How to fully utilize sequencing and analysis of the transcriptome to inform disease
understanding and drug discovery and development
• Improving our understanding of the transcriptome and developing better analysis
strategies to deal with the sheer amount of transcriptional complexity
• Debating methods to make sequencing data analysis simpler, faster and cheaper
• Shifting towards a more targeted analytical approach defined by disease context and
specific sequencing application
Paul Rejto, Head of Precision
Medicine, Oncology Research
Unit, Pfizer
Dongliang Ge, Director,
Computational Biology, Gilead
Sciences
Zoltan Dezso, Principal Scientist,
Human Biology & Data Sciences
Engine, Eisai
4.15 Chair’s Closing Remarks
4.20 End Day Two & Close of Conference
Excellent panel of speakers providing
a comprehensive overview of the field
Vertex Pharmaceuticals
RNA-Seq Attendee

RNA-Seq Forum
@RNASeq_Summit
Pre- Conference Workshop - A
The concept of a liquid biopsy has been around for some time, but is now fast becoming the leading
technology for new diagnostics to detect early stage cancer resulting in more successful treatment,
and to monitor cancer progression after treatment. While much of the focus in liquid biopsy has
been on sequencing the DNA circulating in the patient’s blood, a recent paper in Nature Cell
Biology entitled “Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver”
researchers are focusing on exosomes circulating in the bloodstream; specifically the RNA
contained within these exosomes. Pancreatic cancer is one of the most lethal cancers due
in part to the difficulty in early diagnosis and treatment. Researchers believe sequencing
RNA from tumor derived exosomes circulating in the patient’s blood could lead to
early diagnosis and treatment. This workshop will include in-depth coverage of the
bioinformatics solutions used to analyze and interpret RNA-sequencing results from
these exosome experiments providing additional hypothesis on regulatory networks and
potential isoforms of biological significance.
By attending this workshop you learn about and discuss the following:
• Take a deep dive and understand how to optimize the analysis of RNA-sequencing
results to get the most out of each RNA-seq experiment
• Standardize RNA-sequencing data analysis using industry leading algorithms and statistical
testing
• Understand scalable approaches to sequencing data analysis and optimize the ROI across the organization for
sequencing experiments
• Evaluate a biologist approach to streamlining R NA-sequencing alignment and analysis using configured
workflows for the fast track to biological interpretation
• Analyze exosome gene expression signatures to pinpoint significant genes associated with early detection of
pancreatic cancer
• Identify significantly differentially expressed isoforms and their association to pancreatic cancer
• Generate novel regulatory networks as hypotheses suggesting drivers of the expression changes observed in
these tumor producing exosomes to better understand pancreatic cancer drivers.
Transcriptome Analysis of Pancreatic Cancer Exosomes Reveal
Pathways & Biological Processes Involved in Metastatic Progression
Date: April 26, 2016 | Time: 9:00am – 1:00pm
Workshop leader
Dr. Jamie Hill
Senior Bioinformatics Scientist
QIAGEN
Workshop leader
Dr. Jean-Noel Billaud
Principal Scientist
QIAGEN
Jamie Hill received a Master’s degree in Physics and a
PhD in membrane protein structure prediction under
the supervision of Professor CM Deane in the Statistics
department of the University of Oxford. In 2014 he
was awarded a Marie Curie postdoctoral fellowship
at QIAGEN Aarhus. Today he is the Product Owner of
QIAGEN’s CLC Genomics Workbench.
Jean-Noel Billaud, Ph.D. is Principal Scientist at Qiagen
Bioinformatics. He joined Ingenuity Systems (now
QIAGEN) in 2008 as staff scientist for in silico research
program in oncology and infectious diseases. Jean-Noel
Billaud holds a Ph.D. in Blood Cell Biology from Paris
VII, and has done his post-doctoral work at the Scripps
Research Institute (San Diego, CA).

RNA-Seq Forum
@RNASeq_Summit
Pre- Conference Workshop - B
In recent years the role of the microbiota in health and disease is a field of research that has
exploded with interest and opportunity. We now have a better understanding of how changes to
the composition of our natural microbiome and their products impacts upon the initiation and
development of disease. This has unlocked exciting new avenues for therapeutic intervention.
In order to fully harness these new avenues of treatment, we must first advance our understanding
of the specific role of microbiome communities in the progression of disease. Karsten Zengler
will spearhead this dynamic and interactive session focussed on harnessing the power of RNA
sequencing to provide detailed insight into the composition and function of the microbiota in
a disease specific context. By attending this workshop, you will learn about and debate the
following:
• Analyzing microbiome signatures: identification of gene expression patterns in
complex microbial communities
• Deciphering the data: identifying strategies to maximize value output from
microbiome RNA sequencing
• On the origin of species: delineating and attributing patterns of gene expression
within the microbiome community
• Interpreting microbiota gene expression profiles to detail specific impacts on health and
disease
• Algorithm refining and streamlining to increase the speed of analysis and subsequent application of RNA
sequencing in microbiome research
• Clinically applying metatranscriptomics as a taxonomic biomarker and diagnostic tool
• Developing gold standard universal microbiome RNA sequencing protocols to aid reproducibility and the
verification of microbial influence in disease progression
• Applying metatranscriptomics to guide drug discovery and development
• Creating accurate software packages for Prokaryotic RNA sequencing analysis
Attend this workshop to delve extensively into the subject matter, collaborate with fellow experts in the field, and
hear a multitude of view points and experiences. You will leave better equipped to effectively utilize RNA sequencing to
drive your microbiome disease research.
Successfully Utilizing Metatranscriptomics to Advance Progression in
Microbiome Disease Research
Date: April 26, 2016 | Time: 2:00pm - 5:00pm
Workshop leader
Karsten Zengler
Associate Professor, Division of Host-Microbe Systems & Therapeutics
University of California, San Diego
Karsten Zengler is Associate Professor in the Department of
Pediatrics, Division of Host-Microbe Systems & Therapeutics
at the University of California, San Diego and member of the
leadership team of the Center for Microbiome Innovation.
Prof. Zengler has more than 15 years of experience in the fields
of microbiology and systems biology. He worked for seven years
in the biotechnology industry where he led a team of scientists
to pioneer the high-throughput cultivation for the isolation
and recovery of previously unculturable microorganisms. His
work has focused on microbial ecology and understanding
microorganism interactions with each other, their environment
and their host. He spearheaded the field of community systems
biology where he combined his knowledge in microbial
physiology and molecular biology with computational biology
to discover new physiological capabilities, regulatory effects,
and novel mechanisms of interaction. Dr. Zengler is author and
co-author of more than 50 research articles and reviews as well
as editor of the book “Accessing Uncultivated Microorganisms”.
He founded several companies and is on the advisory board of
different companies and institutions

RNA-Seq Forum
Commercial Partners
@RNASeq_Summit
®
Clontech
Clontech’s comprehensive collection of
SMARTer® NGS kits is built on core SMART®
technology, a powerful process that provides the ability
to read full-length transcript information. With years of
experience and a strong focus on improving the process
of RNA-seq library preparation and the quality of data
produced from every sample, this highly sensitive family
of RNA-seq products is constantly growing in order to
fulfill more demanding research needs.
www.clontech.com
Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in
serving science, with revenues of $17 billion and
approximately 50,000 employees in 50 countries. Our
mission is to enable our customers to make the world
healthier, cleaner and safer. Through our premier brands
– Thermo Scientific, Applied Biosystems, Invitrogen,
Fisher Scientific and Unity Lab Services – we offer an
unmatched combination of innovative technologies,
purchasing convenience and comprehensive support.
For more information, please visit
www.thermofisher.com
QIAGEN
Qiagen is a provider of sample and assay technologies for
molecular diagnostics, applied testing, academic
and pharmaceutical research. Consolidated under the
Dutch holding Qiagen N.V., the company operates more
than 35 offices in over 20 countries.
www.qiagen.com
Fluidigm
Fluidigm creates and manufactures innovative
technologies and life-science tools designed to
revolutionize biology through a relentless pursuit of
scientific truth. Its core technologies are based on
microfluidics and mass cytometry, and enable the
exploration and analysis of individual cells, as well as the
industrial application of genomics.
Fluidigm partners with life science researchers and
enterprises to provide simplified workflows for genomics
and proteomics applications. Whether your quest is to
understand the profiles and functions of single cells or
to meet high-throughput data demands of a production-
scale laboratory, you’ll find a solution at
www.fluidigm.com
Spotlight Partner
Spotlight Partner
Workshop Partner
Lead Partner
Exhibition Partner
Genialis
Genialis builds software that empowers the biologist
or clinician to explore her data autonomously. Genialis
Platform is a complete ecosystem for NGS data
management, analysis, visualization and collaboration.
The Platform boasts Real Time Interactive Visualizations,
a technology we developed to enhance the user
experience and improve the efficiency of data exploration
and discovery.
www.genialis.com

RNA-Seq Forum
Commercial Partners
Contact Us
Contact
Diane McKenna
Portfolio Director - Genomics
Tel: +1 212 537 5898
Email: sponsor@hansonwade.com
Who you will meet...
C-Level
Director Level
Academia
Principal Scientist
64%20%
30%35%
15%
Previous
Attendance by
Seniority
Pharma
Academia
Solution Providers
20%50%
30%
20%
Predicted
Attendance by
Sector
@RNASeq_Summit
Seven Bridges
Seven Bridges is the biomedical data analysis company
accelerating breakthroughs in genomics research for
cancer, drug development and precision medicine. The
scalable, cloud-based Seven Bridges Platform empowers
rapid, collaborative analysis of millions of genomes in
concert with other forms of biomedical data. Thousands
of researchers in government, biotech, pharmaceutical
and academic labs use Seven Bridges, including two of
the largest genomics projects in the world: U.S. National
Cancer Institute’s Cancer Genomics Cloud pilot and
Genomics England’s 100,000 Genomes Project. The
company’s 187 experts work from its Cambridge, MA
headquarters and offices in Belgrade, London and
San Francisco.
www.sbgenomics.com
Dolomite
Dolomite develops and manufactures innovative, open
and versatile droplet systems for handling tens of
thousands of single cells. Applications include high
throughput single cell RNA sequencing, T Cell Receptor
sequencing, high throughput antibody isolation, and
encapsulation of cells in hydrogel beads for culture or
enzymatic reactions. We offer modular, scalable systems
ideal for Single Cell RNA-Seq and a range of chips, and
installation and training.
www.dolomite-microfluidics.com
Exhibition Partner Exhibition Partner

RNA-Seq Forum
Venue and Accommodation
* All discount offers (including team discounts) require payment at the time of registration to receive any discount. ‘Early Bird’ discounts require
payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer.
The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation.
Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees
will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same
organisation can be made at any time.
Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss
or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of
God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.
Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details
may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, 4th Floor, 52
Grosvenor Gardens, London, SW1W 0AU
Hanson Wade Limited. Registered in England & Wales. Company No: 6752216
Terms & Conditions
Register
Event Prices
Pricing & Venue
Industry
Register & Pay before Friday March 18, 2016 Standard Prices
Conference + 2 Workshops $3597 (Save $500) $3797 (Save $300)
Conference + Workshop $3098 (Save $300) $3198 (Save $200)
Conference Only $2499 (Save $200) $2699
Workshop (each) $699
Academic
Register & Pay before Friday March 18, 2016 Standard Prices
Conference + 2 Workshops $2197 (Save $400) $2397 (Save $200)
Conference + Workshop $1898 (Save £200) $1998 (Save $100)
Conference Only $1499 (Save $100) $1599
Workshop (each) $499
@RNASeq_Summit
The Marker Hotel
501 Geary Street
San Francisco
California
94102
Accommodation: Overnight
accommodation is not included
in the registration fee, however
accommodation options will be
sent out with your confirmation
email upon registering.
www.rna-seqsummit.com/register
Tel: +1 212 537 5898
Email: register@hansonwade.com
Mail:
Hanson Wade
4th Floor, 52 Grosvenor Gardens,
London, SW1W 0AU
• 10% discount – 3 delegates
• 15% discount – 4 delegates
• 20% discount – 5 or more delegates
Please note that discounts are only valid
when three or more delegates from one
company book and pay at the same time.
Team Discounts*

4th RNA-Seq San Francisco April 26-28 Event Guide

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (20)

Ähnlich wie 4th RNA-Seq San Francisco April 26-28 Event Guide

Ähnlich wie 4th RNA-Seq San Francisco April 26-28 Event Guide (20)

Mehr von Diane McKenna

Mehr von Diane McKenna (8)

Kürzlich hochgeladen

Kürzlich hochgeladen (20)

4th RNA-Seq San Francisco April 26-28 Event Guide